Table 1.
A detailed account of PBx procedure and patient characteristics, by time period.
| Time period | ||||
|---|---|---|---|---|
| Variable | 2003–2007 | 2008–2012 | 2013–2017 | P |
| Total PBx procedures, n | 2218 | 2798 | 3957 | |
| Age, years, mean (SD) | 65.1 (8.7) | 65.6 (8.5) | 66.5 (8.6) | <0.001 |
| Prophylaxis, n (%) | ||||
| Single‐dose ciprofloxacin | 1865 (85) | 2325 (83) | 2951(75) | <0.001 |
| Extended ciprofloxacin | 282 (13) | 439 (16) | 942 (24) | |
| Other regime | 38 (2) | 30 (1) | 64 (2) | |
| Missing | 33 | 4 | 0 | |
| PSA level (μg/L), n (%) | ||||
| <3 | 82 (4) | 118 (4) | 294 (7) | <0.001 |
| 3–10 | 1163 (53) | 1648 (59) | 2447 (62) | |
| 10–20 | 529 (24) | 569 (20) | 719 (18) | |
| >20 | 433 (20) | 459 (16) | 495 (13) | |
| Missing | 11 | 4 | 2 | |
| Volume of prostate (mL), n (%) | ||||
| < 40 | 1126 (52) | 1393 (51) | 1836 (47) | <0.001 |
| 40–100 | 983 (45) | 1264 (46) | 1896 (49) | |
| > 100 | 56 (2.6) | 90 (3.3) | 153 (3.9) | |
| Missing | 53 | 51 | 73 | |
| Number of PBx cores, n (%) | ||||
| 0–6 | 1064 (48) | 220 (8) | 541 (14) | <0.001 |
| 7–10 | 1140 (52) | 2134 (76) | 2170 (55) | |
| ≥11 | 7 (0.3) | 443 (16) | 1246 (31) | |
| Missing | 7 | 1 | ‐ | |
| PBx procedure*, n (%) | <0.001 | |||
| First | 1784 (80) | 2114 (76) | 2609 (66) | |
| Repeat | 434 (20) | 684 (24) | 1348 (34) | |
| PSAD (ng/mL/mL), n (%) | <0.001 | |||
| <0.1 | 168 (8) | 398 (15) | 791 (20) | |
| 0.10–0.15 | 370 (17) | 577 (21) | 898 (23) | |
| >0.15 | 1622 (75) | 1770 (64) | 2203 (57) | |
P values are from comparisons of the last period (2013–2017) vs the first (2003–2007).
*
Patients included in the study may have been biopsied previous to our study. The numbers presented of repeated PBx procedures are related to our study period, as we have no data on PBx procedures before the 1 May 2003.